| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
Personalized cancer treatments targeting oncogenic mutated genes are currently developing. Since mutated genes are recognized as foreign by the host immune system, they might be an appropriate target for cancer immunotherapy. In the current study, we have identified two antigen epitopes derived from the epidermal growth factor receptor (EGFR) T790M mutation, which is known to cause resistance to gefitinib in non-small cell lung cancer, and one antigen epitope derived from the KRAS (G12V) mutation, which is frequently detected in colorectal cancer. Our results could provide a novel immunotherapeutic approach for treatment against refractory advanced cancer patients with these mutations, and might lead to development of "personalized immunotherapy targeting mutated genes".
|
